- Details
- Andrea hosts Jessica Hawley and Aleksandar Obradovic to discuss their study, published in Cancer Cell, which explores the effects of combining Anti-PD-1 immunotherapy with Androgen Deprivation Therapy (ADT) in metastatic castration-sensitive prostate cancer. The research, part of the PRIME-CUT Study, used advanced techniques like single-cell RNA sequencing and quantitative immunofluorescence to an...
|
- Details
- Zach Klaassen converses with Matthew Cooperberg about findings from the EMBARK study, presented at ESMO and published in the New England Journal. The study focuses on the efficacy of enzalutamide (enza) plus leuprolide versus leuprolide alone in treating high-risk non-metastatic hormone-sensitive prostate cancer. Dr. Cooperberg notes the predictability of better efficacy with combination treatment...
|
- Details
- Michael Morris highlights notable prostate cancer trials, focusing on AMG 509, a bispecific antibody targeting STEAP1 and CD3. This promising early-phase study, still determining optimal dosages, shows potential in treating prostate cancer, a field historically resistant to immune therapy. Dr. Morris emphasizes AMG 509's ability to reduce bony and visceral diseases, including liver disease, with m...
|
- Details
- Zach Klaassen engages with Colin Pritchard in a detailed discussion about genomic testing in prostate cancer. They emphasize the importance of genomic testing, particularly in advanced prostate cancer, for treatment decisions and family counseling. Dr. Pritchard highlights the clinical utility of both germline and somatic testing, especially in metastatic cases, and discusses the timing and types...
|
- Details
- Zach Klaassen speaks with Abhishek Srivastava about the significance of germline and genomic testing in advanced prostate cancer. Dr. Srivastava elaborates on his recent publication, which aims to improve the penetration of such testing in urology, particularly in community practices. He emphasizes the importance of cascade testing for identifying actionable mutations and influencing treatment opt...
|
- Details
- In this discussion, Andrea Miyahira speaks with Ping Mu about his group's paper. The research focuses on the role of SYNCRIP in controlling APOBEC-driven mutagenesis in prostate cancer. Dr. Mu explains that the loss of SYNCRIP leads to a break in the mechanism controlling this mutagenesis driver, resulting in prostate cancer gaining resistance to AR therapy. The conversation highlights the tumor h...
|
- Details
- Neal Shore, Sarah Nielsen, and David Wise discuss broadening access to germline testing for prostate cancer patients. Reflecting on their collective efforts, including the PROCLAIM Trial and an editorial on Universal Genetic Germline Testing for Hereditary Cancer Syndromes, they emphasize democratizing genetic testing and universal accessibility. The conversation delves into the underutilization o...
|
- Details
- Alicia Morgans host Fatima Karzai and Rana McKay to explore the National Cancer Institute Natural History Study. This study focuses on prostate cancer patients with unusual mutations and exceptional responses to treatments, aiming to understand their disease progression over time. The trial, conducted across multiple sites including UCSD, follows participants longitudinally, particularly those wit...
|
- Details
- Elena Castro joins Alicia Morgans in a discussion on the clinical trial landscape for metastatic castration-resistant prostate cancer. When seeing a patient, Elena considers prior therapies and genetic testing, noting BRCA1 and BRCA2 alterations being investigated earlier provide an opportunity to treat patients with different PARP inhibitors. Drs. Morgans and Castro highlight the use of radiophar...
|
- Details
- In this discussion between Alicia Morgans and Kim Chi, they discuss the challenges, controversies, and opportunities of PARP inhibitor combinations with androgen receptor signaling inhibitors. Dr. Kim Chi summarized the MAGNITUDE trial that studied metastatic CRPC patients who received ARPI or abiraterone vs. abiraterone plus niraparib. The trial's pre-screening process selected patients with homo...
|
